---
title: "文件：藥明合聯持有人尋求通過大宗交易籌集至多 24 億港元"
description: "交易條款顯示，藥明合聯生物技術有限公司的持有人合全藥業香港投資有限公司尋求通過大宗交易籌集至多 24 億港元資金：發行 3030 萬股，每股定價 77 至 79.07 港元，較週三收盤價 82.80 港元折讓 4.5% 至 7%，佔現有流通股約 2.47%，賣方鎖定期 90 天，摩根士丹利擔任獨家簿記管理人。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260268080.md"
published_at: "2025-10-08T10:26:30.000Z"
---

# 文件：藥明合聯持有人尋求通過大宗交易籌集至多 24 億港元

> 交易條款顯示，藥明合聯生物技術有限公司的持有人合全藥業香港投資有限公司尋求通過大宗交易籌集至多 24 億港元資金：發行 3030 萬股，每股定價 77 至 79.07 港元，較週三收盤價 82.80 港元折讓 4.5% 至 7%，佔現有流通股約 2.47%，賣方鎖定期 90 天，摩根士丹利擔任獨家簿記管理人。

交易條款顯示，藥明合聯生物技術有限公司的持有人合全藥業香港投資有限公司尋求通過大宗交易籌集至多 24 億港元資金：發行 3030 萬股，每股定價 77 至 79.07 港元，較週三收盤價 82.80 港元折讓 4.5% 至 7%，佔現有流通股約 2.47%，賣方鎖定期 90 天，摩根士丹利擔任獨家簿記管理人。

### Related Stocks

- [02268.HK - 藥明合聯](https://longbridge.com/zh-HK/quote/02268.HK.md)
- [MS.US - 摩根士丹利](https://longbridge.com/zh-HK/quote/MS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/275736820.md) |
| Morgan Stanley Decreases Total Voting Rights in flatexDEGIRO SE to 3.19% | Morgan Stanley has reduced its voting rights in flatexDEGIRO SE from 3.63% to 3.19%, a decrease of 0.44 percentage point | [Link](https://longbridge.com/zh-HK/news/275636914.md) |
| WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM | WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. | [Link](https://longbridge.com/zh-HK/news/275675866.md) |
| J.P. Morgan Appoints Geneva-Based Banker to International Senior Role | J.P. Morgan has appointed Burkhard Koep as the new Global Head of Communications Investment Banking, based in Geneva. Ko | [Link](https://longbridge.com/zh-HK/news/275729531.md) |
| Here's How Much $100 Invested In Morgan Stanley 5 Years Ago Would Be Worth Today | Morgan Stanley (NYSE:MS) has delivered an average annual return of 19.52% over the past 5 years, outperforming the marke | [Link](https://longbridge.com/zh-HK/news/274864800.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。